Not Yet RecruitingNot Applicable

Correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic Fibrosis in MASlD With type2 Diabetes Mellitus

80 participantsStarted 2024-12-01

Plain-language summary

Metabolic dysfunction asociated steatotic liver disease prevalence is 25%world wide diabetic patients have a risk for MASLD then have hepatic fibrosis so we study correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic fibrosis In Metabolic dysfunction asociated steatotic liver disease in patients with type2 Diabetes Mellitus

Who can participate

Age range30 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients of both sex who have type2 Diabetes Mellitus for less than five years Exclusion Criteria:alcholics ,chronic liver disease elevated liver functions , sever infection \-

What they're measuring

degree of hepatic fibrosis in MASLD with type 2 diabetes mellitus

Timeframe: 1 year

Trial details

NCT IDNCT06715189

SponsorSohag University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-01

Contact for this trial

ELZAHRAA K Mohammed, spcialist

01064954825 elzahraaadbelrehem@sohag.edu.eg

View on ClinicalTrials.gov More Hepatic Fibrosis trials